<DOC>
	<DOCNO>NCT00302549</DOCNO>
	<brief_summary>1 . To compare efficacy FK506 vs intravenous cyclophosphamide pulse treatment class III-IV LN . 2 . To compare safety tolerability FK506 vs intravenous cyclophosphamide pulse treatment class III-IV LN . 3 . To explore dose FK506 effective range blood concentration .</brief_summary>
	<brief_title>To Compare Efficacy Safety FK506 v IVC Treatment Class III-IV LN</brief_title>
	<detailed_description>Corticosteroid combine cytotoxic drug regard conventional therapy Class IV Lupus Nephritis ( LN ) , efficacy improve patient ' long term survival . However , treatment fails patient , especially present significant vascular lesion . In addition , cyclophosphamide ( CTX ) severe side effect high incidence marrow inhibition infection.FK506 ( Tacrolimus ) new calcineurin inhibitor . Similar Cyclosporine ( CsA ) , inhibits production IL-2 activation T cell . Furthermore , add value inhibit production IL-10 Th2 cell , thus reduce production auto antibody B cells.It also exert specific immunosuppressive effect CsA-insensitive pathway . FK506 could inhibit activation naive T cell also activation proliferation prim T cells.FK506 10 -100 time powerful CsA inhibit activation T cells.Animal study MRL/lpr mouse LN model demonstrate FK506 could significantly depress excretion urine protein level serum anti-dsDNA , inhibit glomerular cellular proliferation formation crescent , reduce deposit immune complex . A preliminary study show FK506 significantly effective patient IV LN , indicate rapid reduction urine protein , increase serum albumin , decrease auto antibody together remission lesion activity renal tissue . However , drawback study small sample size lack control group . Hence , multi-center control study compare FK506 cytotoxic agent evaluate efficacy safety FK506 patient III IV LN , explore effective range FK506 blood concentration appropriate target patient population would need .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Female patient diagnosis Systemic Lupus Erythematosus ( SLE ) accord criterion American Rheumatic Association , 1982 ( Appendix 1 ) age 1865 year , whose score SLEDAI ( Disease Active Index , Appendix 2 ) great 10 . 2 . Patients diagnosed class III IV LN renal biopsy , accord WHO classification criterion ( 1995 , Appendix 3 ) within 3 month significant active pathological lesion . 3 . Patients proteinuria ≥ 2g/24h , active urine sediment ( Hematuria white cell cast urine ) . 4 . Patients sign write informed consent form ( patient less 18 year old parents/legal representative 's signature ) , give consent follow study procedure followup . 1 . Patients receive treatment cytotoxic drug CTX , Mycophenolate mofetil ( MMF ) cyclosporine 1 week within three month , Azathioprine ( AZa ) accept . 2 . Patients serum creatinine &gt; 3 mg/dl（265μmol/L） . 3 . Patients severe infection central nervous system symptom . 4 . Patients impaired liver function , ALT/GPT AST/GOT twice normal upper limit active hepatitis . 5 . Patients abnormal glucose , fast blood glucose &gt; 6.2 mmol/L post meal blood glucose &gt; 11.2 mmol/L . 6 . Patients pregnant lactate . 7 . Patients know allergic macrolide . 8 . Patients use Erythromycin , Fluconazole , Ethinylestradiol , Rifampicin , Carbamazepine .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Treatment</keyword>
	<keyword>Lupus Nephritis</keyword>
</DOC>